University of Liverpool researchers receive £2.4 million to advance a minimally invasive treatment for keratoconus, aiming to improve patient access and reduce NHS costs.
The Keep Antibiotics Working campaign is back to alert the public to the risks of antibiotic resistance, urging people to always take their doctor, pharmacist or nurse’s advice.
Regina Fluhrer from the University of Augsburg and Bernd Schröder from the TU in Dresden discuss the potential of intramembrane proteases as targets for cancer therapies.
The NHS reports that 1 in 5 women in the UK are currently affected by PCOS, but what do we really know about the condition? It’s imperative that women have a clear understanding of their reproductive health. here, we explain everything you need to know about PCOS.
Dr Gerry Morrow shares his thoughts on the precision medicine, defined as the cost-effectiveness of breakthrough treatments and explains why this area is a priority for both researchers and government.
Patients will benefit from significant government investment in new NHS technology to improve treatment, diagnosis and care options for diseases including cancer.
Dr Elizabeth Robertson, Director of Research at Diabetes UK details the hunt for an alternative to century-old Type 1 diabetes treatment – and looks at how British diabetes research is demanding something better.
NHS England will fund treatment for thousands of people with severe Haemophilia, which will lessen the risk of life-threatening Haemophilia bleeds and reduce treatment time.
Research from the Nuffield Department of Population Health, University of Oxford, supported by Diabetes UK, has shown that helping people with Type 2 diabetes to meet their three treatment targets could lead to significant savings for the NHS.
Chief Executive of Brain Tumour Research, Sue Farrington Smith MBE, outlines the priorities for research into brain tumours and why it is imperative we overcome this uniquely devastating cancer.
Prof Dr Regina Fluhrer, from the University of Augsburg, explains how intramembrane proteases have been implicated in the emergence of neurodegenerative diseases.
